KRAS and cancer: KPT9274 is a small-molecule inhibitor that targets PAK4 and has been studied as a potential cancer therapy in both preclinical and early-stage clinical trials.278 Our group further demonstrated that KPT9274, in combination with KRASG12C inhibitors, has synergistic effects and enhances the anticancer activity of KRAS inhibitors in RASG12C inhibitor-resistant cancer models.279 These findings thus lay the groundwork for clinical studies investigating the effectiveness and safety of combining KPT9274 with sotorasib in patients who have not responded to sotorasib monotherapy.